A phase II study of carboplatin, cisplatin, interferon-alpha, and tamoxifen for patients with metastatic melanoma.

MLA

Gause, B. L., et al. “A Phase II Study of Carboplatin, Cisplatin, Interferon-Alpha, and Tamoxifen for Patients with Metastatic Melanoma.” Cancer Investigation, vol. 16, no. 6, 1998, pp. 374–80. EBSCOhost, https://doi.org/10.3109/07357909809115776.

APA

Gause, B. L., Sharfman, W. H., Janik, J. E., Curti, B. D., Steis, R. G., Urba, W. J., Smith, J. W., 2nd, Alvord, W. G., & Longo, D. L. (1998). A phase II study of carboplatin, cisplatin, interferon-alpha, and tamoxifen for patients with metastatic melanoma. Cancer Investigation, 16(6), 374–380. https://doi.org/10.3109/07357909809115776

Chicago

Gause, B L, W H Sharfman, J E Janik, B D Curti, R G Steis, W J Urba, J W Smith 2nd, W G Alvord, and D L Longo. 1998. “A Phase II Study of Carboplatin, Cisplatin, Interferon-Alpha, and Tamoxifen for Patients with Metastatic Melanoma.” Cancer Investigation 16 (6): 374–80. doi:10.3109/07357909809115776.